Last updated: 2026-09-07 17:16:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lexaria Bioscience Corp. (LEXX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.24, with a market capitalization of $23.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.21 to $23.25. This page covers its latest market performance, valuation, price trends and company information.
$23.38M | |
$13.03 | |
$187.50 | |
$4.21 | |
$12.32 | |
22.16K | |
32.95K | |
-- | |
$23.25 | |
$4.21 | |
-- | |
-- |
Lexaria Bioscience Corp. (LEXX) last closed at $12.32 as of 2026-09-04 23:59:00, unchanged from the previous close of $12.32.
During the latest regular trading session, LEXX traded between $4.21 and $187.50, with a volume of 22.16K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Lexaria Bioscience Corp. (LEXX) moved from $11.68 to $14.24, representing a gain of 21.91% ($2.56).
The stock traded between $10.24 and $14.37 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 161.53 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 52.7%
LEXX is currently trading at $14.24, placing it 52.7% of the way from its 52-week low of $4.21 to its 52-week high of $23.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lexaria Bioscience Corp. (LEXX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.